|Day Low/High||34.17 / 35.35|
|52 Wk Low/High||33.97 / 46.47|
The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.
What new management means for Mylan shareholders moving forward.
Pfizer is in talks to merge its off-patent drug operation with Mylan.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Kimberly-Clark's performance is nothing to sneeze at, and neither is Coca-Cola's, as higher sales, higher prices and big demand from emerging markets appear to give us a return to the good old days of great senior growth stocks.
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
Watch the Russell 2000, housing activity, and mergers and acquisitions.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
The names include a veterinary drug concern plus companies with successful drugs on the market.
These two firms have successful drugs and could make nice additions for larger companies.
I'm inclined to add to Disney on today's weakness.
We also dissect the S&P 500's record run, check out China's latest economic data and take a skeptical glance at an idea floated by a couple Fed officials.
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
Especially when healthcare CEOs discus political issues with analysts and reporters.
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.
Pets can bring significant profits to companies that cater to this niche market.
Selecting the creme de la creme of last year's top dividend dogs generated an average total return of 8.8%.
Pfizer may be done with its two-month correction but the uptrend may not resume right away.
When the stock's inexpensive, hated and devoid of love -- that's when.
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.